Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal ...

Outcomes from targeted axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer in a safety-net medical center. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.

HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...

91.6% of people treated with the Perjeta-based regimen were alive at ten years versus 89.8% of those treated with Herceptin, chemotherapy, and placebo (hazard ratio [HR]=0.83, 95% CI: 0.69-1.00, ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

THP combines one chemotherapy drug (a taxane) with the HER2-targeting drugs trastuzumab and pertuzumab. THP is a standard treatment for patients with metastatic HER2+ breast cancer. Previous small ...

Sara M. Tolaney, MD, MPH, highlights a transformative year for breast cancer research at this year’s ASCO Annual Meeting.